BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33142932)

  • 1. Identifying Cancer-Relevant Mutations in the DLC START Domain Using Evolutionary and Structure-Function Analyses.
    Holub AS; Bouley RA; Petreaca RC; Husbands AY
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33142932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DLC-1:a Rho GTPase-activating protein and tumour suppressor.
    Durkin ME; Yuan BZ; Zhou X; Zimonjic DB; Lowy DR; Thorgeirsson SS; Popescu NC
    J Cell Mol Med; 2007; 11(5):1185-207. PubMed ID: 17979893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional cross-talk between ras and rho pathways: a Ras-specific GTPase-activating protein (p120RasGAP) competitively inhibits the RhoGAP activity of deleted in liver cancer (DLC) tumor suppressor by masking the catalytic arginine finger.
    Jaiswal M; Dvorsky R; Amin E; Risse SL; Fansa EK; Zhang SC; Taha MS; Gauhar AR; Nakhaei-Rad S; Kordes C; Koessmeier KT; Cirstea IC; Olayioye MA; Häussinger D; Ahmadian MR
    J Biol Chem; 2014 Mar; 289(10):6839-6849. PubMed ID: 24443565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Tumor Suppressor DLC-1: Far From Clear.
    Liu X; Pan YJ; Zheng JN; Pei DS
    Anticancer Agents Med Chem; 2017; 17(7):896-901. PubMed ID: 27604574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver.
    Liao YC; Lo SH
    Int J Biochem Cell Biol; 2008; 40(5):843-7. PubMed ID: 17521951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1.
    Sanchez-Solana B; Wang D; Qian X; Velayoudame P; Simanshu DK; Acharya JK; Lowy DR
    Mol Cancer; 2021 Nov; 20(1):141. PubMed ID: 34727930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of structure of Rho GTPase-activating protein DLC-1 on cell morphology and migration.
    Kim TY; Healy KD; Der CJ; Sciaky N; Bang YJ; Juliano RL
    J Biol Chem; 2008 Nov; 283(47):32762-70. PubMed ID: 18786931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function.
    Liao YC; Shih YP; Lo SH
    Cancer Res; 2008 Oct; 68(19):7718-22. PubMed ID: 18829524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DLC-1 tumor suppressor regulates CD105 expression on human non-small cell lung carcinoma cells through inhibiting TGF-β1 signaling.
    Zhang K; Na T; Ge F; Yuan BZ
    Exp Cell Res; 2020 Jan; 386(2):111732. PubMed ID: 31770531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma.
    Ching YP; Wong CM; Chan SF; Leung TH; Ng DC; Jin DY; Ng IO
    J Biol Chem; 2003 Mar; 278(12):10824-30. PubMed ID: 12531887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DLC-1 tumor suppressor is involved in regulating immunomodulation of human mesenchymal stromal /stem cells through interacting with the Notch1 protein.
    Na T; Zhang K; Yuan BZ
    BMC Cancer; 2020 Nov; 20(1):1064. PubMed ID: 33148199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth.
    Durkin ME; Ullmannova V; Guan M; Popescu NC
    Oncogene; 2007 Jul; 26(31):4580-9. PubMed ID: 17297465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma.
    Wong CM; Lee JM; Ching YP; Jin DY; Ng IO
    Cancer Res; 2003 Nov; 63(22):7646-51. PubMed ID: 14633684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms.
    Healy KD; Hodgson L; Kim TY; Shutes A; Maddileti S; Juliano RL; Hahn KM; Harden TK; Bang YJ; Der CJ
    Mol Carcinog; 2008 May; 47(5):326-37. PubMed ID: 17932950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors.
    Ullmannova V; Popescu NC
    Int J Oncol; 2006 Nov; 29(5):1127-32. PubMed ID: 17016643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deleted in Liver Cancer 2 (DLC2) protein expression in hepatocellular carcinoma.
    Wolosz D; Walczak A; Szparecki G; Dwojak M; Winiarska M; Wolinska E; Gornicka B
    Eur J Histochem; 2019 Feb; 63(1):. PubMed ID: 30827083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional analysis of the Drosophila RhoGAP Cv-c protein and its equivalence to the human DLC3 and DLC1 proteins.
    Sotillos S; Aguilar-Aragon M; Hombría JC
    Sci Rep; 2018 Mar; 8(1):4601. PubMed ID: 29545526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma.
    Kim TY; Lee JW; Kim HP; Jong HS; Kim TY; Jung M; Bang YJ
    Biochem Biophys Res Commun; 2007 Mar; 355(1):72-7. PubMed ID: 17292327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development.
    Durkin ME; Avner MR; Huh CG; Yuan BZ; Thorgeirsson SS; Popescu NC
    FEBS Lett; 2005 Feb; 579(5):1191-6. PubMed ID: 15710412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B core protein promotes liver cancer metastasis through miR-382-5p/DLC-1 axis.
    Du J; Bai F; Zhao P; Li X; Li X; Gao L; Ma C; Liang X
    Biochim Biophys Acta Mol Cell Res; 2018 Jan; 1865(1):1-11. PubMed ID: 28982593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.